Pivotal phase III trial of arbaclofen placarbil for the treatment of spasticity in patients with multiple sclerosis. A 13-week double-blind, randomised, placebo-controlled trial followed by an open-label extension.

Trial Profile

Pivotal phase III trial of arbaclofen placarbil for the treatment of spasticity in patients with multiple sclerosis. A 13-week double-blind, randomised, placebo-controlled trial followed by an open-label extension.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Arbaclofen placarbil (Primary)
  • Indications Multiple sclerosis; Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Sponsors XenoPort
  • Most Recent Events

    • 20 May 2013 Status changed from active, no longer recruiting to completed, as reported by a Xenoport media release.
    • 20 May 2013 Co-primary endpoints 'Statistically significant improvements in scores on the Ashworth Scale and the 7-point Patient Global Impression of Change scale' have not been met, as reported by a XenoPort media release.
    • 23 Mar 2013 182 patients (91% of the targeted enrollment) have been enrolled to date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top